Financière de Tubize S.A.
TUB
Rank in Stocks
#2119
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Share Price
$217.90
Last synced: 2026-10-20
Market Cap
$9.70B
Change (1 day)
5.57%
Change (1 year)
-19.89%
Country
BE
Trade Financière de Tubize S.A. (TUB)
Category
Healthcare
P/B ratio for Financière de Tubize S.A. (TUB)
P/B ratio as of October 2026 TTM: 3.88
According to Financière de Tubize S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.88. At the end of 2023 the company had a P/B ratio of 1.78.
P/B ratio history for Financière de Tubize S.A. from 2003 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.88 | 12.83% |
| 2024 | 3.44 | 93.61% |
| 2023 | 1.78 | -1.27% |
| 2022 | 1.80 | 45.33% |
| 2021 | 1.24 | -5.96% |
| 2020 | 1.32 | 23.95% |
| 2019 | 1.06 | -8.04% |
| 2018 | 1.15 | -16.50% |
| 2017 | 1.38 | 2.53% |
| 2016 | 1.35 | -13.33% |
| 2015 | 1.56 | 7.29% |
| 2014 | 1.45 | 7.13% |
| 2013 | 1.35 | 40.45% |
| 2012 | 0.96 | 37.78% |
| 2011 | 0.70 | 3.15% |
| 2010 | 0.68 | -15.07% |
| 2009 | 0.80 | 63.65% |
| 2008 | 0.49 | -56.17% |
| 2007 | 1.11 | -37.19% |
| 2006 | 1.77 | -9.56% |
| 2005 | 1.96 | -22.63% |
| 2004 | 2.53 | -19.22% |
| 2003 | 3.14 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 61.05% |
US
|
|
| 13.2547 | 241.50% |
US
|
|
| 4.208 | 8.42% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 59.29% |
NL
|
